sections

Tuesday, 23 July 2019

Upfront

Sort by: Newest firstOldest firstA-ZZ-A

  • Public or private?

    Two car makers on opposite sides of the world are playing out a debate that rages in every fast-growing company: when is the right time to go public?

  • Bondi rescue

    Australia’s distant bond market may seem an odd place for a landmark blockchain experiment. Nothing, however, could be further from the truth.

  • AAA for ESG

    Asian rating agencies are paying closer attention to environmental, social and governance risks. If it helps build confidence in their methodologies, that is a welcome step.

  • Posturing in Pakistan

    The IMF’s warning earlier this year that China’s emergence as the world’s biggest bilateral creditor could cause problems in future debt reckonings is finally catching the attention of its largest shareholder, the US.

  • Bad medicine

    Even in the new-fangled world of biotechnology, there is no such thing as a panacea. Ascletis Pharma, the first biotech company to go public under Hong Kong’s new listing rules, has done more harm than good.

  • Summer heat

    This summer is proving unusually hot for Asia’s capital markets – and it’s nothing to do with the record temperatures in parts of Japan.

  • India's bond chase

    India is taking another step along the path towards a vibrant corporate bond market. It needs to get there, quickly.

  • Project: impossible

    Asia’s first securitisation of project finance loans is cause for celebration. Keeping the party going, however, will be another story.

  • Strained connections

    Last week’s spat over the Stock Connect link between Hong Kong and China has dredged up some uncomfortable questions over the future of the parallel markets. It needn’t have.

  • Xiaomi's reboot

    What a relief. Xiaomi’s first week as a listed company has drawn a line under the recent run of shaky IPOs from China’s technology sector – but it could have been very different.